CVRx flags Barostim evidence ahead of HFSA, with REBALANCE late-breaking on Oct. 11

CVRx says it has new clinical evidence for its Barostim heart-failure device ahead of HFSA in October, including late-breaking REBALANCE real-world registry analyses scheduled for Oct. 11 and first real-world evidence in HFmrEF. Barostim results from the BENEFIT-HF trial will be shown in the meeting’s clinical trial ePoster hub.